Effect of the thiazolidinediones on cardiovascular risk factors

Lucia Gilling, Pitiporn Suwattee, Cyrus DeSouza, Sunil Asnani, Vivian Fonseca

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

Rosiglitazone and pioglitazone are medications from the thiazolidinedione class of compounds currently available for the treatment of type 2 diabetes mellitus. Traditionally used to enhance insulin sensitivity and decrease plasma insulin levels, added applications have emerged beyond those involving glycemic control. Cardiovascular risk factors associated with insulin resistance such as elevated blood pressure, dyslipidemia, abnormal fibrinolysis, and endothelial and vascular dysfunction have been shown to improve after thiazolidinedione treatment. Therapy with rosiglitazone or pioglitazone has been found to modify vascular reactivity and other processes involved in atherosclerosis. There may be differences between the agents in their effects on plasma lipid characteristics and particle size. These agents serve as excellent adjuncts to oral and insulin therapy for patients with type 2 diabetes mellitus and hold promise for the prevention of cardiovascular disease associated with the insulin resistance syndrome. Clinical trials are in progress to determine whether such therapy will lead to a reduction in cardiovascular events.

Original languageEnglish (US)
Pages (from-to)149-156
Number of pages8
JournalAmerican Journal of Cardiovascular Drugs
Volume2
Issue number3
DOIs
StatePublished - Jan 1 2002

Fingerprint

Thiazolidinediones
rosiglitazone
pioglitazone
Insulin Resistance
Type 2 Diabetes Mellitus
Blood Vessels
Insulin
Therapeutics
Fibrinolysis
Dyslipidemias
Particle Size
Atherosclerosis
Cardiovascular Diseases
Clinical Trials
Blood Pressure
Lipids

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Effect of the thiazolidinediones on cardiovascular risk factors. / Gilling, Lucia; Suwattee, Pitiporn; DeSouza, Cyrus; Asnani, Sunil; Fonseca, Vivian.

In: American Journal of Cardiovascular Drugs, Vol. 2, No. 3, 01.01.2002, p. 149-156.

Research output: Contribution to journalReview article

Gilling, Lucia ; Suwattee, Pitiporn ; DeSouza, Cyrus ; Asnani, Sunil ; Fonseca, Vivian. / Effect of the thiazolidinediones on cardiovascular risk factors. In: American Journal of Cardiovascular Drugs. 2002 ; Vol. 2, No. 3. pp. 149-156.
@article{fd054423f4e846498affa8ab45da79ab,
title = "Effect of the thiazolidinediones on cardiovascular risk factors",
abstract = "Rosiglitazone and pioglitazone are medications from the thiazolidinedione class of compounds currently available for the treatment of type 2 diabetes mellitus. Traditionally used to enhance insulin sensitivity and decrease plasma insulin levels, added applications have emerged beyond those involving glycemic control. Cardiovascular risk factors associated with insulin resistance such as elevated blood pressure, dyslipidemia, abnormal fibrinolysis, and endothelial and vascular dysfunction have been shown to improve after thiazolidinedione treatment. Therapy with rosiglitazone or pioglitazone has been found to modify vascular reactivity and other processes involved in atherosclerosis. There may be differences between the agents in their effects on plasma lipid characteristics and particle size. These agents serve as excellent adjuncts to oral and insulin therapy for patients with type 2 diabetes mellitus and hold promise for the prevention of cardiovascular disease associated with the insulin resistance syndrome. Clinical trials are in progress to determine whether such therapy will lead to a reduction in cardiovascular events.",
author = "Lucia Gilling and Pitiporn Suwattee and Cyrus DeSouza and Sunil Asnani and Vivian Fonseca",
year = "2002",
month = "1",
day = "1",
doi = "10.2165/00129784-200202030-00002",
language = "English (US)",
volume = "2",
pages = "149--156",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Effect of the thiazolidinediones on cardiovascular risk factors

AU - Gilling, Lucia

AU - Suwattee, Pitiporn

AU - DeSouza, Cyrus

AU - Asnani, Sunil

AU - Fonseca, Vivian

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Rosiglitazone and pioglitazone are medications from the thiazolidinedione class of compounds currently available for the treatment of type 2 diabetes mellitus. Traditionally used to enhance insulin sensitivity and decrease plasma insulin levels, added applications have emerged beyond those involving glycemic control. Cardiovascular risk factors associated with insulin resistance such as elevated blood pressure, dyslipidemia, abnormal fibrinolysis, and endothelial and vascular dysfunction have been shown to improve after thiazolidinedione treatment. Therapy with rosiglitazone or pioglitazone has been found to modify vascular reactivity and other processes involved in atherosclerosis. There may be differences between the agents in their effects on plasma lipid characteristics and particle size. These agents serve as excellent adjuncts to oral and insulin therapy for patients with type 2 diabetes mellitus and hold promise for the prevention of cardiovascular disease associated with the insulin resistance syndrome. Clinical trials are in progress to determine whether such therapy will lead to a reduction in cardiovascular events.

AB - Rosiglitazone and pioglitazone are medications from the thiazolidinedione class of compounds currently available for the treatment of type 2 diabetes mellitus. Traditionally used to enhance insulin sensitivity and decrease plasma insulin levels, added applications have emerged beyond those involving glycemic control. Cardiovascular risk factors associated with insulin resistance such as elevated blood pressure, dyslipidemia, abnormal fibrinolysis, and endothelial and vascular dysfunction have been shown to improve after thiazolidinedione treatment. Therapy with rosiglitazone or pioglitazone has been found to modify vascular reactivity and other processes involved in atherosclerosis. There may be differences between the agents in their effects on plasma lipid characteristics and particle size. These agents serve as excellent adjuncts to oral and insulin therapy for patients with type 2 diabetes mellitus and hold promise for the prevention of cardiovascular disease associated with the insulin resistance syndrome. Clinical trials are in progress to determine whether such therapy will lead to a reduction in cardiovascular events.

UR - http://www.scopus.com/inward/record.url?scp=0036318847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036318847&partnerID=8YFLogxK

U2 - 10.2165/00129784-200202030-00002

DO - 10.2165/00129784-200202030-00002

M3 - Review article

C2 - 14727977

AN - SCOPUS:0036318847

VL - 2

SP - 149

EP - 156

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 3

ER -